摘要
目的 比较奈达铂为主的联合化疗方案与顺铂为主的联合化疗方案对晚期恶性肿瘤的疗效.方法 262例患者分别为非小细胞肺癌、食管癌、胃癌、乳腺癌、大肠癌、卵巢癌等,随机分为试验组和对照组,两组疾病分布基本均衡,试验组(以奈达铂为主的联合化疗组)130例,对照组(以顺铂为主的联合化疗组)132例.化疗方案试验组与对照组分别为:非小细胞肺癌、卵巢癌TN和TP方案;食管癌、大肠癌FLN与FLP方案;胃癌FAN与FAP方案;乳腺癌CAN与CAP方案.每4周为1个化疗周期,2个化疗周期后评定疗效.结果 试验组缓解率50.8%,显著高于对照组的40.2%(P<0.05),其中试验组对食管癌和卵巢癌的缓解率高于对照组;试验组的胃肠道不良反应显著低于对照组,但骨髓毒性显著高于对照组(P值均<0.05).结论 奈达铂为新一代有效的广谱抗肿瘤药物,其联合化疗疗效较顺铂好,尤其适用于食管癌和卵巢癌,可作为一线药物推荐.
Objective The efficacies of nedaplatin-combined chemotherapy were compared with those of cisplatin-combined chemotherapy in patients with advanced malignant tumors. Methods Two hundred and sixty-two patients were divided into two groups randomly, the nedaplatin(NDP) group (M94, F36, median age 58y) and the eisplatin(Cis) group (M95, F37, median age 57y). Cycles were repeated every 4 weeks. Effects were assessed after 2 cycles. First-line schedules were chosen, and nedaplatin and cisplatin were used respectively. Results The results showed that the remission rate (50.8 %) in NDP group was significantly higher than that (40.2 %) in Cis group (P<0.05). The NDP had better efficacy than Cis especially in treating ovary cancer and esophageal cancer. The toxicity of NDP was milder for gastro-intestinal tract but more serious for bone marrow than that of Cis(P<0.01). Conclusion As a new broad-spectrum anti-tumor agent, NDP could be a better choice than cisplatin in the treatment of malignant tumors. It is especially of better efficacy in treating ovary cancer and esophageal cancer, and could be recommended as the first-line drugs.
出处
《肿瘤研究与临床》
CAS
2008年第10期688-689,694,共3页
Cancer Research and Clinic
